Advertisement

Topics

Latest "NIGU Chemie GmbH" News Stories

00:47 EST 16th November 2018 | BioPortfolio

Here are the most relevant search results for "NIGU Chemie GmbH" found in our extensive news archives from over 250 global news sources.

More Information about NIGU Chemie GmbH on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about NIGU Chemie GmbH for you to read. Along with our medical data and news we also list NIGU Chemie GmbH Clinical Trials, which are updated daily. BioPortfolio also has a large database of NIGU Chemie GmbH Companies for you to search.

Showing "NIGU Chemie GmbH" News Articles 1–25 of 1,100+

Thursday 15th November 2018

MetrioPharm AG: MetrioPharm AG Expands Patent Protection for its Lead Compound MP1032 to Canada

EQS Group-News: MetrioPharm AG / Key word(s): Patent 15.11.2018 / 17:53 Zurich, November 15, 2018. MetrioPharm AG announces that a substance patent for its lead compound MP1032 has been obtained in Canada. The Canadian patent CA 2791327 was granted on October 30, 2018. MetrioPharm AG now has broad protection for MP1032 in all major markets: In Europe, the United States, Australia, New Z...


DGAP-News: Die CytoTools AG hat einen neuen Ankerinvestor gewonnen, den Anteil an der DermaTools Biotech GmbH erhöht und damit erste Voraussetzungen für die geplanten europäischen Phase-III-Studien geschaffen (deutsch)

Die CytoTools AG hat einen neuen Ankerinvestor gewonnen, den Anteil an der DermaTools Biotech GmbH erhöht und damit erste Voraussetzungen für die geplanten europäischen Phase-III-Studien geschaffen...

Dr. Anthony Tolcher Joins the Scientific Advisory Board of NBE-Therapeutics

Basel, Switzerland, November 15, 2018 / B3C newswire / -- NBE Therapeutics AG, a biopharmaceutical company developing next-generation immune-stimulatory antibody-drug conjugates (iADCs™) for improved cancer therapy, today announces the appointment of Dr. Anthony Tolcher to NBE's Scientific Advisory Board (SAB). Dr. Tolcher is a Board certified Medical Oncologist from San Antonio, TX, U.S.A., wi...


Bayer-Aktie (Wochenchart): Neues Verlaufstief

Düsseldorf (www.aktiencheck.de) - Bayer-Chartanalyse von HSBC Trinkaus & Burkhardt: Die Analysten von HSBc Trinkaus & Burkhardt nehmen in einer aktuellen Aktienanalyse die Aktie des Chemie- und Pha...

Biotest AG: Biotest AG acquires ninth plasma collection center in Germany

DGAP-News: Biotest AG / Key word(s): Miscellaneous 15.11.2018 / 07:00 The issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest AG acquires ninth plasma collection center in Germany - 100% subsidiary Plasma Service Europe takes over plasma centre in Hanover - In the future, 20 plasma collection centres in Europe to ensure long-term plasma supply D...

Wednesday 14th November 2018

Roivant Sciences raises $200mm in private placement

Roivant Sciences GMBH raised $200mm in a private placement financing ($7bn post-money valuation) with new investors NovaQuest...

Merck: Q3-Ergebnis weiter stark durch negative Währungseffekte belastet - Aktie herabgestuft!

Hannover (www.aktiencheck.de) - Merck-Aktienanalyse von Analyst Thorsten Strauß von der Nord LB: Thorsten Strauß, Analyst der Nord LB, stuft in einer aktuellen Aktienanalyse die Aktie des Chemie- u...

Original-Research: M1 Kliniken AG (von First Berlin Equity Research GmbH)

Original-Research: M1 Kliniken AG - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu M1 Kliniken AG Unternehmen: M1 Kliniken AG ISIN: DE000A0STSQ8 Anlass der Studie: Update Empfehlung: BUY seit: 14.11.2018 Kursziel: 19,20 Euro Kursziel auf Sicht von: 12 Monaten Letzte Ratingänderung: - Analyst: Christian Orquera First Berlin Equity Research has publis...

CytRx Corp CYTR Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryCytRx Corp CytRx is a clinical state is a biopharmaceutical company focusing on the research and development of novel treatments for cancer. The company's oncology based product comprises of its lead drug product candidate, aldoxorubicin formerly INNO206. Aldoxorubicin is a prodrug of the commonly prescribed chemotherapeutic doxorubicin, designed to reduce adverse events by controlling rele...

4SC AG VSC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

Summary4SC AG 4SC is a biopharmaceutical company that discovers and develops small molecule drugs for the treatment of cancer and autoimmune diseases. The company's product focuses on epigenetics, cancer stem cells and cancer immunotherapy. Its product pipeline comprises therapeutic programs at various stages of clinical development and earlystage research projects including Resminostat, 4SC202 an...

Top Oncologist, Dr Samuel Fourie, Joins Advisory Board of AzarGen Biotechnologies

Stellenbosch, South Africa, November 14, 2018 / B3C newswire / -- AzarGen Biotechnologies (Pty) Ltd (Stellenbosch, South Africa), a company focused on developing human therapeutic proteins using advanced genetic engineering and synthetic biology techniques in plants, is pleased to announce that Dr. Samuel Fourie, an oncology specialist, has joined as a Clinical Advisor. Dr. Fourie qualified in 19...

STADA-Anleihen: Ankündigung einer Weisung zur Bestellung dinglicher Sicherheiten

Bad Marienberg (www.anleihencheck.de) - Die STADA Arzneimittel AG (STADA) (ISIN DE0007251803/ WKN 725180) ist von ihrer Mehrheitsaktionärin Nidda Healthcare GmbH (Nidda) darüber informiert worden, ...

Formycon Reports Nine-Month Figures for 2018

DGAP-News: Formycon AG / Key word(s): 9-month figures 14.11.2018 / 08:00 The issuer is solely responsible for the content of this announcement.   Press Release // November 14, 2018 Formycon Reports Nine-Month Figures for 2018   - Turnover increases to 32.42 million euros - Net results for the period amount to 8.06 million euros and continue to be influenced by one-off eff...

Tuesday 13th November 2018

Merger between Eckert & Ziegler BEBIG SA (BEBIG) and Eckert & Ziegler Strahlen - und Medizintechnik AG (EZAG) - Announcement of the filing of the Joint Terms of Merger

Press release  REGULATED INFORMATION Merger between Eckert & Ziegler BEBIG SA (BEBIG) and Eckert & Ziegler Strahlen - und Medizintechnik AG (EZAG) - Announcement of the filing of the common draft terms of the cross-border merger (Joint Terms of Merger) and availability of the merger documentation. Seneffe, Belgium, November 13, 2018. BEBIG announced the filing on 8 November...

Mexico Crown and Bridge Materials Market Outlook to 2025 [Report Updated: 10092018] Prices from USD $4995

Mexico Crown and Bridge Materials Market Outlook to 2025SummaryGlobalData's new report, Mexico Crown and Bridge Materials Market Outlook to 2025, provides key market data on the Mexico Crown and Bridge Materials market. The report provides value, in millions of US dollars, volume in units and average prices USD within market segments Permanent Bridges and Permanent Crowns.The report also provides...

STADA's EUR300,000,000 1.75% Senior Notes due 2022: announcement of an instruction to grant in rem securities

STADA Arzneimittel AG / Key word(s): Bond STADA's EUR300,000,000 1.75% Senior Notes due 2022: announcement of an instruction to grant in rem securities 13-Nov-2018 / 16:45 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcem...

Ambu A/S: Annual Report 2017/18 (Earnings release)

Ambu ends the year with 15% organic growth and an EBIT margin of 21.6%. Following a 2.5 percentage point EBIT margin increase, Ambu is on track to realising the targets of its 2020 strategy. "We have now come to the end of the first year of our three-year strategy period, and we have created solid growth in our business. Our key figures and ratios are sa...

Monday 12th November 2018

Merck: Starke Wachstumsimpulse erwartet

Kulmbach (www.aktiencheck.de) - Merck-Aktienanalyse von "Der Aktionär": Marion Schlegel, Redakteurin des Anlegermagazins "Der Aktionär", nimmt in einer aktuellen Aktienanalyse die Aktie des Chemie-...

RetiPharma Secures Funding to Develop Treatments of Degenerative Eye Disorders

Advancing novel mode-of-action drug and building a unique translational in vivo platform Copenhagen, Denmark, November 12, 2018 / B3C newswire / -- RetiPharma, focusing on the development of products for the treatment of degenerative eye disorders based on an in vivo platform for translation from in vivo models to humans, is pleased to announce that it has secured funding from the Novo Nordisk Fo...

Global Fatigue Tester Market Status and Outlook 20182025 [Report Updated: 19082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynamics Regulations and Global Market OverviewPart 2:Upstream Raw Materials / Components Manufacturing Procurement Methods Channels and Cost , Major Regional Production Overview and Trade FlowPart 3:Pr...

Saturday 10th November 2018

Icon Genetics GmbH Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 17092018] Prices from USD $250

SummaryIcon Genetics GmbH Icon Genetics a subsidiary of Denka Co Ltd is a platform technology company that offers plant engineering technologies. The company develops, manufactures and markets biopharmaceutical product candidates, engineered organisms and technology platforms for plant biotechnology and plantbased production. It commercializes proprietary transgene operating systems suites of tech...

Microcrystalline Cellulose MCC Market by Application Food Beverage, Pharmaceutical, Cosmetics Personal Care,, Raw Material Source Woodbased, Nonwoodbased, and Region North America, Europe, APAC, RoW Global Forecasts to 2023 [Report Updated: 28082018] P

The MCC market is projected to register a CAGR of 7.0% from 2018 to 2023, in terms of value The market size of microcrystalline cellulose MCC is estimated at USD 885.1 million in 2018 and is projected to reach USD 1,241.4 million by 2023, at a CAGR of 7.0% between 2018 and 2023. MCC is widely used in pharmaceutical, food beverage, and cosmetic personal care applications. As it is chemically iner...

JenaValve Technology Inc Medical Equipment Deals and Alliances Profile [Report Updated: 15102018] Prices from USD $250

SummaryJenaValve Technology Inc JenaValve Technology, a subsidiary of JenaValve Technology GmbH, is a medical device company that develops and manufactures transcatheter aortic valve replacement TAVR systems for transapical and transfemoral implantation. The company's TAVR system is an investigational device used as a therapeutic alternative to surgical aortic valve replacement for highrisk patien...

Friday 9th November 2018

Haplogen GmbH Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12092018] Prices from USD $250

SummaryHaplogen GmbH Haplogen is a biopharmaceutical company that improves human health by fighting against infectious diseases such as common cold, dengue fever, influenza and hepatitis C. The company utilizes its proprietary genetics technology platform to identify novel pathogen host factors and develops therapeutics for the treatment of infectious diseases. It undertakes the construction of ne...

Global and Asia Terpinene Market Status and Future Forecast 20132023 [Report Updated: 21082018] Prices from USD $3000

SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Type, Application RegionPart 2:Global Market by company, Type, Application RegionPart 3:Asia Market by company, Type, Application RegionPart 410:Key Regions of Asia Market by Type, ApplicationPart 11:Company information, Sales, Cost, Margin etc.Part 12:ConclusionMarket Segment as fo...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks